[go: up one dir, main page]

WO2008144690A3 - Compositions and methods for enhancing active agent absorption - Google Patents

Compositions and methods for enhancing active agent absorption Download PDF

Info

Publication number
WO2008144690A3
WO2008144690A3 PCT/US2008/064233 US2008064233W WO2008144690A3 WO 2008144690 A3 WO2008144690 A3 WO 2008144690A3 US 2008064233 W US2008064233 W US 2008064233W WO 2008144690 A3 WO2008144690 A3 WO 2008144690A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
methods
active agent
agent absorption
enhancing active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/064233
Other languages
French (fr)
Other versions
WO2008144690A2 (en
Inventor
Chung Shih
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NexusPharma Inc
Original Assignee
NexusPharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/805,202 external-priority patent/US8426466B2/en
Application filed by NexusPharma Inc filed Critical NexusPharma Inc
Priority to EP08755962.1A priority Critical patent/EP2150243A4/en
Publication of WO2008144690A2 publication Critical patent/WO2008144690A2/en
Publication of WO2008144690A3 publication Critical patent/WO2008144690A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compositions and methods for enhancing the absorption of active agents across the mucosa of animal subjects are provided. Compositions having biodegradable linkages are included, conferring decreased likelihood of toxicity. Methods of use and appropriate dosage forms are also provided.
PCT/US2008/064233 2007-05-21 2008-05-20 Compositions and methods for enhancing active agent absorption Ceased WO2008144690A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP08755962.1A EP2150243A4 (en) 2007-05-21 2008-05-20 Compositions and methods for enhancing active agent absorption

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11/805,202 2007-05-21
US11/805,202 US8426466B2 (en) 2006-05-22 2007-05-21 Compositions and methods for enhancing active agent absorption
US409907P 2007-11-21 2007-11-21
US61/004,099 2007-11-21

Publications (2)

Publication Number Publication Date
WO2008144690A2 WO2008144690A2 (en) 2008-11-27
WO2008144690A3 true WO2008144690A3 (en) 2009-02-26

Family

ID=40122287

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/064233 Ceased WO2008144690A2 (en) 2007-05-21 2008-05-20 Compositions and methods for enhancing active agent absorption

Country Status (2)

Country Link
EP (1) EP2150243A4 (en)
WO (1) WO2008144690A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104906592B (en) * 2011-02-25 2017-11-03 广州南沙龙沙有限公司 Branched Linkers for Protein Drug Conjugates
EP3031905A4 (en) * 2013-08-07 2017-04-26 Kyoto University Method for producing pancreatic hormone-producing cell

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817624A (en) * 1995-06-05 1998-10-06 Alza Corporation Permeation enhancer compositions for increased absorption of therapeutic proteins through the colonic membrane
WO2001054514A1 (en) * 2000-01-27 2001-08-02 Aqua Solution Inc. Composition for intestinal delivery
WO2003057170A2 (en) * 2002-01-07 2003-07-17 Emisphere Technologies, Inc. Oral insulin therapy
CN1857727A (en) * 2006-03-13 2006-11-08 新疆维吾尔自治区畜牧科学院兽医研究所 Animal skin penetrant

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773647A (en) 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817624A (en) * 1995-06-05 1998-10-06 Alza Corporation Permeation enhancer compositions for increased absorption of therapeutic proteins through the colonic membrane
WO2001054514A1 (en) * 2000-01-27 2001-08-02 Aqua Solution Inc. Composition for intestinal delivery
WO2003057170A2 (en) * 2002-01-07 2003-07-17 Emisphere Technologies, Inc. Oral insulin therapy
CN1857727A (en) * 2006-03-13 2006-11-08 新疆维吾尔自治区畜牧科学院兽医研究所 Animal skin penetrant

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MENG, B. ET AL.: "Hypoglycemic effect of insulin W/O microemulsions following intestinal administration to rats.", ZHONGGUO YAOKE DAXUE XUEBAO., vol. 37, no. 4, 2006, pages 304 - 307, ISSN: 1000-5048 *
See also references of EP2150243A4 *

Also Published As

Publication number Publication date
EP2150243A4 (en) 2013-08-21
WO2008144690A2 (en) 2008-11-27
EP2150243A2 (en) 2010-02-10

Similar Documents

Publication Publication Date Title
BRPI0806531A2 (en) COMPOUND, PHARMACEUTICAL COMPOSITION, THERAPEUTIC AGENT, AND USE OF THE COMPOUND.
WO2007077561A3 (en) Compositions and methods for enhancing in-vivo uptake of pharmaceutical agents
ZA200807767B (en) Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient
CL2007002017A1 (en) COMPOUNDS DERIVED FROM [4,5 '] - BIPIRIMIDINIL-6,4'-DIAMINE; PHARMACEUTICAL COMPOSITION; AND USE AS AN INHIBITOR OF THE ACTIVITY OF CINASA IN CANCER DE VEJIGA, CANCER CERVICAL AND MIELOMA MULTIPLE.
CL2007002513A1 (en) COMPOUNDS DERIVED FROM SUBSTITUTED ISOINDOLIN, INTERMEDIATE COMPOUNDS; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT AND PREVENTION OF DISEASES SUCH AS CANCER, PAIN, MACULAR DEGENERATION, AMONG OTHERS.
CR8642A (en) COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE IN THE TREATMENT OF METABOLIC DISORDERS
WO2007127333A3 (en) Compositions for the treatment and prevention of eyelid swelling
IL196108A0 (en) Active agent formulations, methods of making, and methods of use
WO2006042146A3 (en) Multifunctional nanoparticles conjugates and their use
WO2007087068A3 (en) Inhibitors of tyrosine kinases and uses thereof
EP2476461A3 (en) Formulations For Cancer Treatment
IL184051A (en) Acylated glp-1 compounds, pharmaceutical compositions comprising them and their use in the manufacture of medicaments
BRPI0718688A2 (en) LOW IRRITATION COMPOSITIONS AND METHODS FOR PREPARING THE SAME.
WO2005069865A3 (en) Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
TW200745124A (en) Azepinoindole derivatives as pharmaceutical agents
CL2007002920A1 (en) COMPOUNDS DERIVED FROM 2-AMINOCARBONYLPIRIDINE; PHARMACEUTICAL COMPOSITION; AND USE FOR THE TREATMENT OF OCLUSIVE VASCULAR DISORDERS.
WO2009061431A3 (en) Compositions for the treatment and prevention of eyelid swelling comprising an osmotically active ingredient and a vasoconstrictor
WO2009071689A3 (en) 5-halogen-substituted oxindole derivatives and use thereof for treating vasopressine-dependent diseases
CL2007003038A1 (en) COMPOUNDS DERIVED FROM 2-PHENYL-6-AMINOCARBONIL-PYRIMIDINE; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF OCLUSIVE VASCULAR DISORDERS.
SI1909843T1 (en) Antitumoral bioconjugates of hyaluronic acid or its derivatives obtained by indirect chemical conjugation, and their use in the pharmaceutical field
MX2007010560A (en) Roflumilast for the treatment of diabetes mellitus.
CY1117174T1 (en) USE OF 24-norUDCA FOR TREATMENT OF US CHOLOGICAL DISEASES
WO2009156182A3 (en) Uracil derivatives and use thereof
PT2056805E (en) USE OF 2.5-DI-HYDROXYBENZENE DERIVATIVES FOR THE TREATMENT OF TISSUE REACTION
WO2010074936A3 (en) Enzastaurin for the treatment of cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08755962

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2008755962

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE